Melinta Therapeutics Announces Appointment of Peter Piliero as Vice President of Medical Affairs

Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announces the appointment of Dr. Peter Piliero as Vice President of Medical Affairs, effective today.

Dr. Piliero, an Infectious Disease specialist and global Medical Affairs leader, joins Melinta under the leadership of President and Chief Executive Officer Christine Ann Miller. In this role, Dr. Piliero will be responsible for the development and implementation of integrated medical plans for Melinta’s portfolio. Additionally, Dr. Piliero will help Melinta continue to stand out as a thought leader in the important conversations happening in scientific and medical communities today.

“As Melinta continues its legendary journey serving patients with critical, unmet needs, I am excited to welcome Pete to the team. With his depth of medical and scientific experience and proven track record leading high-performing teams, I know he’ll be an incredible asset in driving growth and guiding Melinta’s public discussions as we shape the future of acute care,” Ms. Miller said.

Dr. Piliero joins Melinta from GSK Consumer Healthcare, where he led Medical Affairs Americas. Prior to that role, he held significant clinical and leadership positions at Boehringer Ingelheim, Merck and Mallinckrodt. At these organizations, he led global Medical Affairs teams in various therapeutic areas, including Virology, Immunology, CNS, Metabolism and Women’s Health.

Prior to joining the pharmaceutical industry, Dr. Piliero was Associate Professor of Medicine at Albany Medical College. He practiced there for 11 years as an Infectious Disease and HIV specialist, providing patient care and directing the Clinical Pharmacology Studies Unit.

Since 2017, Dr. Piliero has been an active member of the Medical Affairs Professional Society. He is currently a member of the Board of Directors and the Vice Chair of the Executive Committee.

“I am honored to work alongside this truly committed team to achieve our vision – ensuring that all patients with life-threatening illnesses who need our innovative therapies will receive them,” Dr. Piliero said. “I look forward to developing and executing strategic medical plans, leading scientific communications, generating new evidence, and ensuring trusted communications with external stakeholders to pave the way for improved patient outcomes.”

About Melinta Therapeutics

Melinta Therapeutics, LLC provides innovative therapies to people impacted by acute and life-threatening illnesses. Our portfolio currently includes five commercial-stage antibiotics: Baxdela® (delafloxacin), Kimyrsa™ (oritavancin), Minocin® (minocycline) for Injection, Orbactiv® (oritavancin), and Vabomere® (meropenem and vaborbactam). With an unsurpassed commitment to providers and the patients they serve, we work to ensure that all people who need our therapies can receive them. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact. At Melinta, we’re visionaries dedicated to innovation while staying grounded in what matters most: patients. Visit www.melinta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005500/en/